MILGAMMA Mono 300 film -coated tablets, 100 pcs

Instructions for use for MILGAMMA Mono 300 film -coated tablets, 100 pcs

Detailed instructions for MILGAMMA Mono 300 film -coated tablets, 100 pcs

Field of use

Your choice for nerve damage (neuropathies) through vitamin B1 deficiency. Milgamma® Mono 300 compensates for the vitamin B1 deficiency. The accompanying symptoms of nerve damage, such as tingling, burning and numbness in your feet, can be alleviated. The vitamin B1 active ingredient Benfotiamine in Milgamma® Protekt is particularly well received by the body.
Also suitable for diabetics: diabetics have an increased risk of vitamin B1 deficiency and associated nerve damage. An early act pays off.

Mode of action

Milgamma Mono 300 film -coated tablets (pack size: 100 pc) contain the vitamin B1 in the form of 300 mg of benfotiamine. As a result, Milgamma Mono 300 film -coated tablets (pack size: 100 pc) can help you with neurapathies that are associated with a lack of vitamin B1.

Active ingredients / ingredients / ingredients

1 Film -coated tablet from Milgamma Mono 300 film -coated tablets (pack size: 100 pc) contains:

1 film-coated tablet contains 300 mg of benfotiamine (fat-soluble vitamin B1 derivative).

other ingredients:
Microcrystalline cellulose, talkum, povidone (K30), high-disperses silicon dioxide, croscarmellose sodium, higher chain partial glycerides, hypromellosis, titanium dioxide, polyethylene glycol, saccharin-sodium

Contradictions

Milgamma ® Mono 300 must not be taken if you are allergic to Benfotiamine, Thiamin (chemical name for vitamin B1) or one of the other components of this medicine mentioned in Section 6 of the instructions.

dosage

Application recommendation of Milgamma Mono 300 film -coated tablets (pack size: 100 pc):

The recommended dose is 1 film -coated tablet once a day. The film -coated tablets are taken with some liquid. For the therapy of neuropathies, Milgamma® Protekt should initially be taken over a period of at least 3 weeks. This is followed by further treatment according to the therapeutic success. The duration of taking Milgamma® Protekt depends on the therapeutic success. If there is no or too little effect after four weeks, the therapy of the symptoms should be checked. Please speak to your doctor or pharmacist if you have the impression that the effect of Milgamma® Protekt is too strong or too weak.

Taking

• The film -coated tablets will be chewed with taken some liquid.

Patient information

• Wateriness and ability to use machines:
  • There are no special precautions required.

Pregnancy

• If you are pregnant or breastfeed, or if you suspect that you are pregnant or intend to become pregnant, ask your doctor or pharmacist for advice before taking this drug.
• Pregnancy
  • If you are pregnant, this drug is only useful for the treatment of a proven vitamin B1 deficiency due to its amount of active ingredient. Therefore, you may only apply the preparation if your treating doctor considers this absolutely necessary. During pregnancy, the recommended daily intake for vitamin B1 is 1.2 mg in the 2nd trimester and 1.3 mg in the 3rd trimester. The safety of an application is not yet proven more than the daily dose.
• Breastfeeding
  • If you breastfeed, this drug is only useful for the treatment of a proven vitamin B1 deficiency due to its amount of active ingredient. Therefore, you may only apply the preparation if your treating doctor considers this absolutely necessary. During breastfeeding, the recommended daily intake for vitamin B1 is 1.3 mg. The safety of an application is not yet proven more than the daily dose. Vitamin B1 passes into breast milk.

Hints

mILGAMMA® Mono 300. Active ingredient: Benfotiamin 300 mg. Areas of application: Therapy or prophylaxis of clinical vitamin B1 deficiency states, provided that they cannot be remedied; Treatment of neuropathies and cardiovascula. Sturgeon., D. can be caused by vitamin B1 deficiency. Read the package supplement and ask your doctor or pharmacist for risks and side effects. |2| Wörwag Pharma GmbH & Co